INTRODUCTION {#s1}
============

Tuberculosis (TB) is a serious infectious disease that results in 2.0 million deaths per year \[[@R1]\]. Although pulmonary TB is the most common form of TB infections, extrapulmonary tissues are often infected as well \[[@R2]\]. For example, tuberculous pleurisy is common in extrapulmonary TB \[[@R3]\] and accounts for ∼4.0% of all TB cases in western countries and ∼20% of all TB cases in South Africa \[[@R4]-[@R6]\]. Despite 6.0--9.0 months of anti-TB drug treatment, tuberculous pleurisy might still result in pleural fibrosis, calcification, and thickening. To prevent these complications, corticosteroids are frequently used in addition to conventional anti-TB drugs.

The efficacy and safety of corticosteroids on tuberculous pleurisy were conflicting. Two non-randomized controlled trials (RCTs) \[[@R7], [@R8]\] showed that corticosteroids could promote pleural fluid absorption and reduce pleural thickening; however, Galarza et al \[[@R9]\] demonstrated that no significant difference in the lung capacity, pleural sequelae, and pleural fluid reabsorption rate between corticosteroid and placebo group. In addition, a non-RCT conducted by Mansour et al \[[@R10]\] also showed that the difference was not statistically significant after 6 months; therefore, the effect of adjunctive corticosteroids on tuberculous pleural effusion remains uncertain and controversial.

In this study, the potential benefits and detriments of corticosteroids in treating tuberculous pleural effusion were assessed by reviewing and analyzing RCTs and non-RCTs.

RESULTS {#s2}
=======

Search of the published literature {#s2_1}
----------------------------------

The systematic literature search identified 802 studies on corticosteroids, of which 17 trials comprised patients with tuberculous pleurisy. After excluding 7 studies, 10 trials were included in this analysis that involved 957 tuberculous pleurisy patients \[[@R8]-[@R10], [@R18]-[@R24]\]. Figure [1](#F1){ref-type="fig"} and [Supplementary File 1](#SD1){ref-type="supplementary-material"} show the reasons for the exclusion of various studies.

![Procedures used for trial selection\
Abbreviations: RCT, randomized controlled trial; Non-RCT, non-randomized controlled trial.](oncotarget-08-83315-g001){#F1}

Bias risk of each item for the included RCTs is shown in [Supplementary Figure S1](#SD1){ref-type="supplementary-material"} and Table [S1](#SD1){ref-type="supplementary-material"}. Only Lee et al \[[@R20]\]. reported "high risk" in Free of the selected reporting items shown in [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}. The trial results were analyzed for sensitivity by removing the items of high-risk bias. The quality scores of non-RCTs are summarized in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}. Most of the observational studies suggested reasonably good-quality RCTs with a score of 5 or higher on the Jadad scale.

Studies included in the assessment {#s2_2}
----------------------------------

Ten studies on corticosteroid use (six randomized studies and four cohort studies) between 1958 and 2006 were included in the study (Table [1](#T1){ref-type="table"}) and comprised 957 patients \[[@R8]-[@R10], [@R18]-[@R24]\]. Of these 10 studies, two were conducted in South Korea \[[@R18], [@R21]\], and two in India \[[@R8], [@R24]\]; the others were conducted in Uganda \[[@R19]\], South Africa \[[@R22]\], Taiwan \[[@R20]\], England \[[@R23]\], and Iraq \[[@R10]\]. Nine trials comprised both men and women; 62% (men, from 47 to 97%). The follow-up period ranged from 6.0 months \[[@R22]\] to 46 months \[[@R9]\]. Nine studies included prednisone or placebos as an adjunct to the anti-TB regimen, including INH (isoniazid), RM (rifampin), PZA (pyrazinamide), EMB (ethambutol), SM (streptomycin) (except in Mansour, which did not state them in detail) \[[@R8], [@R9], [@R18]-[@R24]\]. Corticosteroids were given orally in various doses (0.75--1.0 mg/kg/day) \[[@R8]-[@R10], [@R19], [@R20], [@R22], [@R23]\]. The patients in the Bang and Lee \[[@R18], [@R21]\] studies were injected with 1.0 mg/kg/d and 30 mg/d corticosteroids, and the patients in Mansour et al \[[@R24]\] were treated with 125--250 mg intrapleural hydrocortisone.

###### Characteristics of studies included in the meta-analysis

  Study                      Year                                                 Study period   Location       No of cases   Age (mean)    Gender Male (%)   Anti-TB regimen         Corticosteroid
  -------------------------- ---------------------------------------------------- -------------- -------------- ------------- ------------- ----------------- ----------------------- ------------------------------------------------------------
  Lee \[[@R20]\]             1988                                                 1983-1987      Taiwan         40            29            60%               INH 300 mg/d            Prednisolone 0.75 mg/kg/d po
  RM 450 mg/d                                                                                                                                                                         
  EMB 20 mg/kg/d                                                                                                                                                                      
  Galarza \[[@R9]\]          1995                                                 1985-1992      Spain          117           27            51%               INH 300 mg (5mg/kg/d)   Prednisolone 1 mg/kg/d po
  RM 600 mg/d (10 mg/kg/d)                                                                                                                                                            
  Wyser \[[@R22]\]           1996                                                 1994-1995      South Africa   70            33            61%               EMB 10 mg/kg/d          Prednisolone 0.75 mg/kg/d po
  INH 8 mg/kg/d                                                                                                                                                                       
  PZA 25 mg/kg/d                                                                                                                                                                      
  Pyridoxine 25 mg/kg/d                                                                                                                                                               
  Bang \[[@R18]\]            1997                                                 1991-1994      Korea          83            34            59%               INH 400 mg/d            Prednisolone 1 mg/kg/d injection
  RM 600 mg/d                                                                                                                                                                         
  PZA 1500 mg/d                                                                                                                                                                       
  EMB 800 mg/d                                                                                                                                                                        
  Lee \[[@R21]\]             1999                                                 1990-1997      Korea          82            32            64%               INH (NS)                Prednisolone 30 mg/d injection
  RM                                                                                                                                                                                  
  PZA                                                                                                                                                                                 
  EMB                                                                                                                                                                                 
  Streptomycin                                                                                                                                                                        
  Elliott \[[@R19]\]         2004                                                 1988-2002      Uganda         194           34            58%               EMB 20 mg/kg/d          Prednisolone 50, 40, 25, 15 mg/d (respectively 14 days) po
  INH 5 mg/kg/d                                                                                                                                                                       
  RM 10 mg/kg./d                                                                                                                                                                      
  PZA 18-26 mg/kg/d                                                                                                                                                                   
  Aspin \[[@R23]\]           1958                                                 1955-1957      England        30            NA            NA                INH 300 mg/d            ACTH 40 units/d or prednisone 20 mg/d po
  SM 1g/d                                                                                                                                                                             
  Menon \[[@R8]\]            1964                                                 1959-1962      India          49            25 and \>25   47%               INH 200 mg/d            Intrapleural
  SM 1g/d                    Hydrocortisone 25 mg/d or prednisolone 15 mg/d/ po                                                                                                       
  Mathur \[[@R24]\]          1965                                                 1958-1962      India          102           4-75          62%               INH 300 mg/d            Intrapleural
  SM 1g/d                    Hydrocortisone 125-250 mg                                                                                                                                
  Mansour \[[@R10]\]         2006                                                 2003-2004      Iraq           190           17-45         97%               Anti-TB (NS)            Prednisolone 30mg/d po

Abbreviation: INH, isoniazid; SM, streptomycin; PAS, p-amino-salicylic acid; RM, rifampin; EMB, ethambutol; PZA, pyrazinamide; NS, not stated in detail

The outcomes comprised pleural effusion reabsorption (six studies reported the outcome at 4.0 weeks \[[@R8], [@R9], [@R18]-[@R20], [@R24]\] and six studies reported the outcome at 8.0 weeks, \[[@R8], [@R18]-[@R21]\]), the presence of pleural thickening (seven trials), \[[@R8]-[@R10], [@R20]-[@R22], [@R24]\] and adhesions (two trials) \[[@R18], [@R20]\] number of days to achieve improved symptoms and signs (three trials), \[[@R10], [@R18], [@R20]\], 7-d relief of clinical symptoms (two trials), \[[@R20], [@R24]\] death from any cause (one trial), \[[@R19]\] and adverse effects (seven trials).\[[@R9], [@R18]-[@R22], [@R24]\]

Primary outcomes {#s2_3}
----------------

Four RCTs and two non-RCTs comprising 585 cases reported pleural effusion reabsorption at 4.0 weeks \[[@R8], [@R9], [@R18]-[@R20], [@R24]\]. Compared to placebos or non-corticosteroids, adjunctive corticosteroid use reduced the residual fluid at 4.0 weeks (RR = 0.41, 95% CI: 0.22--0.78, *p* = 0.006) (Figure [2](#F2){ref-type="fig"}). In addition, six trials reported pleural effusion reabsorption at 8.0 weeks in 550 patients. Our study showed that corticosteroids did not appear to provide statistically significant benefits for reducing residual pleural effusion after 8.0 weeks in the treatment of tuberculous pleurisy (RR = 0.47, 95% CI: 0.22--1.03, *P* = 0.06) (Figure [3](#F3){ref-type="fig"}).

![Results of the meta-analysis on studies evaluating adjunctive corticosteroid use on reabsorption of pleural effusion at 4.0 weeks: response rate = 0.41 (95% confidence interval: 0.22--0.78)](oncotarget-08-83315-g002){#F2}

![Adjunctive corticosteroid uses on reabsorption of pleural effusion at 8.0 weeks: response rate = 0.47 (95% confidence interval: 0.22--1.03)](oncotarget-08-83315-g003){#F3}

Seven trials reported pleural thickening in 650 patients. There was no statistically significant difference between the corticosteroid and non-corticosteroid group (RR = 0.97, 95% CI: 0.77--1.23, *p* = 0.83) ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). Two RCTs comprising 53 cases also reported no difference in pleural adhesions (RR = 0.75, 95% CI: 0.51--1.11, *p* = 0.15) ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}).

Secondary outcomes {#s2_4}
------------------

Three included trials \[[@R10], [@R18], [@R20]\] reported that corticosteroids could decrease the number of days of clinical symptoms (WMD =-3.32, 95% CI: -4.84---1.79, *p* \< 0.0001) (Figure [4](#F4){ref-type="fig"}). In addition, two trials \[[@R20], [@R24]\] that reported 7-d clinical symptoms concluded that there was no difference in results between the corticosteroid and non-corticosteroid groups (RR = 0.87, 95% CI: 0.00--162.23, *p =* 0.96) ([Supplementary Figure 5](#SD1){ref-type="supplementary-material"}).

![Adjunctive corticosteroid uses on the number of days of clinical symptoms: weighted mean difference = -3.32 (95% confidence interval: -4.84---1.79)](oncotarget-08-83315-g004){#F4}

Adverse events {#s2_5}
--------------

The risk of adverse events (AEs) between the corticosteroid and control groups in patients with tuberculous pleurisy was assessed. Six RCTs and one non-RCT comprising 688 cases examined the statistical difference between the groups on the risk of AE (RR = 2.80, 95% CI: 1.12--6.98, *p* = 0.03) (Figure [5](#F5){ref-type="fig"}). The risk of adverse events (8%) were existed on corticosteroid group as compared with patients who did not receive corticosteroid.

![Adverse effects of adjunctive corticosteroid: response rate = 2.80 (95% confidence interval: 1.12--6.98)](oncotarget-08-83315-g005){#F5}

Limited data are available regarding the effects of corticosteroids on mortality in tuberculous pleurisy. Only one trial assessed the risk of death and found that the mortality rate was not significantly decreased in patients using corticosteroids (RR = 0.92, 95% CI 0.65--1.32).

In addition, only one trial \[[@R19]\] reported the effect of corticosteroids on HIV-associated infections (gastroenteritis, cryptococcal meningitis, esophageal candidiasis, herpes simplex, herpes zoster, and oral thrush) and found that the result was not significantly different in patients using corticosteroids (RR = 13.00, 95% CI 0.74--227.63).

Sensitivity analysis and publication bias {#s2_6}
-----------------------------------------

The above results did not change by using the random-effects model and fixed-effects model. The funnel plot of all items are shown in the Supplementary Information ([Supplementary Figures 6--12](#SD1){ref-type="supplementary-material"}). The Egger's and Begg's tests showed no publication bias (*P* = 0.12 and *P* = 0.21, respectively).

DISCUSSION {#s3}
==========

This systematic review suggests that adjunctive corticosteroid use did not appear to exhibit improved long-term efficacy and might induce more detrimental effects, although the risk of residual pleural fluid at 4.0 weeks and the number of days to symptom improvement were reduced.

The conclusions drawn from different studies about using corticosteroids in addition to anti-TB drugs in patients with tuberculous pleurisy have been inconsistent. The first related RCT conducted by Lee et al \[[@R20]\], 40 patients with tuberculous pleurisy showed that corticosteroid administration could relieve the clinical symptoms and decrease pleural effusion (*p* \< 0.05) compared to those in the placebo group, but their study failed to confirm whether corticosteroid use reduced pleural thickening; however, a non-RCT conducted by Mansour et al \[[@R10]\], 190 patients with tuberculous pleural effusion showed that the results were no longer statistically significant after 6.0 months and they concluded that corticosteroid therapy was unnecessary in the management of tuberculous pleural effusion. A previous systematic review comprising six RCTs and 633 patients conducted by Engel et al \[[@R25]\]. suggested that corticosteroid use was concerned with absorption of residual pleural fluid after 4.0 weeks (RR = 0.76, 95% CI: 0.62--0.94, *p* = 0.0095) and reduced pleural thickening (RR = 0.69, 95% CI: 0.51--0.94, *p* = 0.019). An overview of the above results indicates that there is no strong evidence to assess whether steroids are effective in the treatment of tuberculous pleurisy. In our meta-analysis, we found no proof to favorably support the effect of corticosteroids on residual pleural fluid after 8.0 weeks (RR = 0.72, 95% CI: 0.46--1.12, *p* = 0.14) and pleural adhesions in patients with tuberculous pleurisy (RR = 0.75, 95% CI: 0.51--1.11, *p* = 0.15), and the effect of corticosteroids on pleural thickening was also insignificant (RR = 0.97, 95% CI: 0.77--1.23, *p* = 0.83). Moreover, corticosteroids had a detrimental adverse effect on patients with tuberculous pleurisy (RR = 2.80, 95% CI: 1.12--6.98, *p* = 0.03). This difference between the two studies could be explained by the inclusion of non-RCTs in our meta-analysis.

The detail Resolution of symptoms: dyspnoea, cough, night sweats, tiredness, appetite, pleuritic chest pain, and general well-being were each graded from 0 to 100 using a visual analogue scale and combined index with a maximum score of 700 was calculated. Because of the lack of consistent results, more trials are urgently needed to evaluate the effect of corticosteroids on symptoms. We reanalyzed the number of days of clinical symptoms and found that the time to disappearance of symptoms was significantly shorter in participants who received corticosteroids (WMD =-3.32, 95% CI: -4.84---1.79, *p* \< 0.0001). In addition, Lee \[[@R20]\] demonstrated that fever, dyspnea, and chest pain were more likely to be resolved by 7 d after treatment in patients who received corticosteroids compared to those who received the placebo.

Potential adverse effects of prednisone were well recognized and occurred in the corticosteroids group ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). For example, in the study of Elliott et al \[[@R19]\] treatment was discontinued in 9 of the 97 patients in both groups because of the onset of hyperglycemia, hypertension, infections, and other adverse effects. Wyser et al \[[@R22]\]. reported epigastric pain in 4 of the 34 cases in the corticosteroid group and 3 of the 36 cases in the control group. Lee et al \[[@R20], [@R21]\]. reported epigastric pain in one case in the corticosteroid group but none in the non-corticosteroid group, and Bang et al \[[@R18]\]. reported epigastric pain in one case in the corticosteroid group but none in the non-corticosteroid group. In general, more patients experienced AEs in the corticosteroid group.

This meta-analysis is the latest to examine the effect of corticosteroids in the treatment of tuberculous pleurisy. First, it considered the difference in the design of corticosteroids and traditional therapy in tuberculous pleurisy. Second, it combined data from both RCTs and non-RCTs, thus significantly increasing statistical reliability. Finally, the results remained unchanged on sensitivity analysis. Limitations of our review were that this meta-analysis included only published studies in indexed journals and did not consider unpublished studies; however, no evidence of substantial publication bias was found.

CONCLUSIONS {#s4}
===========

Our results suggest that adjunctive corticosteroid use does not improve the long-term efficacy of tuberculous pleurisy and might lead to detrimental adverse effects, although the ratio of residual pleural fluid (4.0 weeks) to the number of days for symptom improvement was reduced. Thus, corticosteroid treatment might not be necessary in the management of tuberculous pleurisy, and clinicians should make a decision for use by justifying the risk-to-benefit ratio of adjunctive corticosteroid treatment in patients with tuberculous pleurisy.

MATERIALS AND METHODS {#s5}
=====================

Search strategy {#s5_1}
---------------

The data were extracted from quality articles in PubMed, Cochrane, Medline, Embase, Web of Science, Chinese National Knowledge Infrastructure, and reference lists, and by manual searches in July 2015, using the following terms: 'tuberculous pleurisy', placebo, ''corticosteroids, "steroids, 'TB, 'residual fluid, pleural thickening, clinical symptoms, 'adverse events (AE), pleural adhesions.

Data extraction and quality assessment {#s5_2}
--------------------------------------

Trials were excluded if they did not meet with the following inclusion criteria. The following inclusion criteria were used for determining which trials to use in the study: 1) trials that compared corticosteroids with a control (placebo or no steroids); 2) trials that enrolled tuberculous pleurisy cases; and 3) trials that reported results on residual fluid, pleural thickening, pleural adhesions, clinical symptoms, adverse events, and death. Two independent investigators (AP and SX) assessed each inclusion trial and extracted the data, such as trial characteristics and outcome measures (e.g., pleural thickening, pleural adhesions, adverse events, *p* values, response rate \[RR\] for residual fluid, 95% confidence interval \[CI\], and weighted mean difference \[WMD\] for number of days of clinical symptoms). The quality of RCTs was assessed using the Jadad scale, and the non-RCT studies were estimated using the 9-star Newcastle--Ottawa Scale \[[@R11], [@R12]\]. Details of exactly data were extracted from each article in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}.

A list of excluded articles and reasons of exclusion were showed in [Supplementary File 1](#SD1){ref-type="supplementary-material"} and Figure [1](#F1){ref-type="fig"}.

Statistical analyses {#s5_3}
--------------------

The outcomes were analyzed by Review Manager 5.0. *x*^*2*^ and *I*^*2*^ tests were used to assess whether the outcome of the trials had heterogeneity \[[@R13]\]. *p* \< 0.1 or *I*^*2*^ \> 50% was considered heterogeneous. \[[@R14]\] If heterogeneity was detected, the random-effects model was performed to analyze the outcomes \[[@R15]\]. In addition, funnel plots and the Egger's and Begg's tests were performed to evaluate publication bias \[[@R16]\]. The trial results were analyzed for sensitivity by removing the items of "high-risk bias" \[[@R17]\].

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s6}
==========================================
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